Press Releases Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Market Closed - Japan Exchange Other stock markets 11:30:00 10/05/2024 am IST			5-day change	1st Jan Change
3,185 ^JPY	-1.09%		-12.86%	+3.07%

08/05	Japanese Shares Swing to Red Amid Profit-Taking, US Rate Cut Uncertainty	MT
20/03	Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kissei Pharmaceutical : Notice Concerning Status of Acquisition and Completion of the Company's Own Shares	19/03	PU
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares	01/03	PU
Kissei Pharmaceutical : KORSUVA® IV Injection Syringe for Dialysis 17.5μg, 25.0μg and 35.0μg to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis	12/12	PU
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares	01/12	PU
Kissei Pharmaceutical : Introduces Natural Language Processing System	17/11	PU
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares	01/11	PU
Kissei Pharmaceutical : Notice Concerning Revisions to Financial Results Forecast	27/23/27	PU
Kissei Pharmaceutical : Results of Japanese Phase III Clinical Study of KORSUVA® IV Injection for Pruritus in Patients undergoing Hemodialysis Published in NEJM Evidence	23/23/23	PU
Kissei Pharmaceutical : Supplementary Explanatory Materials on Financial Results for the Three Months ended June 30, 2022	05/22/05	PU
Kissei Pharmaceutical : Consolidated Financial Results for the Three Months Ended June 30, 2022	05/22/05	PU
Rigel Pharmaceuticals, Inc. - Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia	22/21/22	AQ
Kissei Pharmaceutical : Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib	30/18/30	PU
Kissei Pharmaceutical : Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for the Treatment of Overactive Bladder	21/18/21	PU
Kissei Pharmaceutical : Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia	30/18/30	PU
Kissei Pharmaceutical : Announces New President and COO	23/18/23	PU
Kissei Pharmaceutical : JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study	17/18/17	PU
Kissei Pharmaceutical : Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" Launches in Japan	06/17/06	PU
Kissei Pharmaceutical : Marketing Approval for Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" was Obtained in Japan	27/17/27	PU
Kissei Pharmaceutical : Exclusive License Agreement for Avacopan, a selective inhibitor of the Complement C5a Receptor, for Rare Kidney Diseases, in Japan	09/17/09	PU
Kissei Pharmaceutical : and Maruishi to collaborate for development and sales/marketing of kappa opioid receptor agonist, "MR13A9", in Japan	13/17/13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kissei Pharmaceutical Co., Ltd.

Equities

4547

JP3240600001

Press Releases

Filters